10.00EUR+0.50%Mkt Cap: 19.99M EURP/E: 1.84Last update: 2026-06-01
Marinomed Biotech AG operates as a biopharmaceutical company in Austria, other European countries, and internationally. Its lead products include Budesolv for the treatment of allergic rhinitis in late-stage clinical dev…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap19.99M EUR
Enterprise Value28.92M EUR
Revenue (TTM)7.96M EUR
Gross Profit979.99K EUR
Net Income (TTM)-15.42M EUR
Revenue/Share4.326 EUR
Last Price10.00 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees32
CountryAT
SectorHealthcare
IndustryBiotechnology
ISINATMARINOMED6
Valuation
P/E (Trailing)1.84
P/E (Forward)4.34
PEG—
EV/EBITDA602.19
EV/Revenue3.63
P/S2.50
P/B-3.25
EPS (TTM)5.44
EPS (Forward)2.29
52W Range
8.60011% of range21.00
52W High21.00 EUR
52W Low8.600 EUR
Profitability
Gross Margin20.64%
Oper. Margin-427.74%
EBITDA Margin0.60%
Profit Margin-324.76%
ROE58.93%
ROA-188.39%
Growth
Revenue Growth-76.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-2.40M EUR
CapEx (TTM)—
FCF Margin-23.98%
FCF Yield-9.55%
Net Debt10.61M EUR
Net Debt/EBITDA220.92
Balance Sheet
Debt/Equity-1.08
Current Ratio0.25
Quick Ratio0.22
Book Value/Sh-3.0580 EUR
Cash/Share0.5170 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.0 (Buy)
Target (Mean)50.00 EUR
Target Range50.00 EUR – 50.00 EUR
# Analysts1
Ownership
Shares Out.2.00M
Float1.32M
Insiders24.30%
Institutions17.30%
Technical
SMA 5012.48 (-19.9%)
SMA 20017.54 (-43.0%)
Beta-0.16
S&P 52W Chg27.70%
Avg Vol (30d)5.23K
Avg Vol (10d)2.20K
Technical Indicators
RSI (14)34.2
MACD-0.8409
MACD Signal-0.9960
MACD Hist.+0.1551
BB Upper11.16 EUR
BB Middle10.10 EUR
BB Lower9.027 EUR
BB Width21.15%
ATR (14)0.6114 EUR
Vol Ratio (20d)0.02x